 Jane Gross
Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 6 | 2025 | 378 | 3.320 |
Why?
| | Cystic Fibrosis | 9 | 2025 | 1063 | 2.970 |
Why?
| | Pulmonary Medicine | 2 | 2024 | 80 | 1.640 |
Why?
| | Nontuberculous Mycobacteria | 5 | 2025 | 228 | 1.350 |
Why?
| | Mycobacterium abscessus | 2 | 2022 | 111 | 1.260 |
Why?
| | Cross Infection | 2 | 2021 | 196 | 1.230 |
Why?
| | Bronchiectasis | 1 | 2025 | 110 | 0.860 |
Why?
| | Muscular Atrophy, Spinal | 1 | 2023 | 22 | 0.840 |
Why?
| | Pyrrolidines | 1 | 2023 | 69 | 0.820 |
Why?
| | Dust | 2 | 2023 | 99 | 0.800 |
Why?
| | Respiratory Insufficiency | 2 | 2023 | 313 | 0.760 |
Why?
| | Mycobacterium | 1 | 2023 | 111 | 0.750 |
Why?
| | Neuromuscular Diseases | 1 | 2023 | 106 | 0.750 |
Why?
| | Quinolones | 1 | 2023 | 127 | 0.740 |
Why?
| | Curriculum | 2 | 2024 | 925 | 0.690 |
Why?
| | Indoles | 1 | 2023 | 372 | 0.680 |
Why?
| | Pyrazoles | 1 | 2023 | 405 | 0.660 |
Why?
| | Pyridines | 1 | 2023 | 477 | 0.650 |
Why?
| | Infection Control | 1 | 2019 | 134 | 0.600 |
Why?
| | Lung Diseases | 3 | 2019 | 723 | 0.590 |
Why?
| | Silicon Dioxide | 1 | 2018 | 111 | 0.570 |
Why?
| | Environmental Exposure | 2 | 2018 | 464 | 0.560 |
Why?
| | Pneumonia | 1 | 2023 | 599 | 0.560 |
Why?
| | Betacoronavirus | 3 | 2020 | 252 | 0.420 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 342 | 0.370 |
Why?
| | Coronavirus Infections | 3 | 2020 | 338 | 0.360 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2025 | 315 | 0.350 |
Why?
| | Disease Transmission, Infectious | 2 | 2020 | 57 | 0.340 |
Why?
| | Vaping | 2 | 2019 | 55 | 0.300 |
Why?
| | Humans | 22 | 2025 | 129116 | 0.260 |
Why?
| | Drug Combinations | 2 | 2023 | 329 | 0.230 |
Why?
| | Risk Factors | 3 | 2025 | 9767 | 0.220 |
Why?
| | Pandemics | 3 | 2020 | 1491 | 0.220 |
Why?
| | Chloride Channel Agonists | 1 | 2023 | 78 | 0.200 |
Why?
| | Mycobacterium avium Complex | 1 | 2023 | 90 | 0.200 |
Why?
| | Respiration | 1 | 2023 | 191 | 0.200 |
Why?
| | Benzodioxoles | 1 | 2023 | 107 | 0.190 |
Why?
| | Aminophenols | 1 | 2023 | 146 | 0.180 |
Why?
| | Water | 1 | 2023 | 444 | 0.170 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 51 | 0.170 |
Why?
| | Societies, Medical | 1 | 2024 | 749 | 0.170 |
Why?
| | September 11 Terrorist Attacks | 1 | 2019 | 32 | 0.160 |
Why?
| | Aerosols | 1 | 2020 | 172 | 0.160 |
Why?
| | Adenoviridae Infections | 1 | 2019 | 16 | 0.160 |
Why?
| | Inhalation Exposure | 1 | 2019 | 91 | 0.160 |
Why?
| | Sex Factors | 1 | 2025 | 1953 | 0.160 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2024 | 375 | 0.160 |
Why?
| | Measles | 1 | 2019 | 44 | 0.150 |
Why?
| | Volcanic Eruptions | 1 | 2018 | 7 | 0.150 |
Why?
| | Incidence | 1 | 2025 | 2635 | 0.150 |
Why?
| | Safety Management | 1 | 2018 | 116 | 0.140 |
Why?
| | Sleep | 1 | 2023 | 676 | 0.140 |
Why?
| | United States | 4 | 2024 | 13938 | 0.140 |
Why?
| | Adult | 4 | 2023 | 35510 | 0.140 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 150 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 894 | 0.130 |
Why?
| | Occupational Exposure | 1 | 2019 | 311 | 0.130 |
Why?
| | Disease Outbreaks | 1 | 2019 | 343 | 0.130 |
Why?
| | Pediatrics | 1 | 2024 | 1062 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 764 | 0.130 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1671 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2021 | 1359 | 0.110 |
Why?
| | Ectodermal Dysplasia 1, Anhidrotic | 1 | 2014 | 1 | 0.110 |
Why?
| | Air Pollutants | 1 | 2018 | 312 | 0.110 |
Why?
| | Sweat | 1 | 2014 | 47 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2018 | 736 | 0.110 |
Why?
| | Military Personnel | 1 | 2019 | 518 | 0.100 |
Why?
| | Chlorides | 1 | 2014 | 138 | 0.100 |
Why?
| | Infant, Newborn | 1 | 2024 | 5739 | 0.100 |
Why?
| | Risk Assessment | 2 | 2018 | 3260 | 0.100 |
Why?
| | Mutation | 1 | 2023 | 3700 | 0.100 |
Why?
| | Colorado | 1 | 2022 | 4394 | 0.100 |
Why?
| | Female | 5 | 2025 | 68510 | 0.100 |
Why?
| | Prospective Studies | 1 | 2023 | 7079 | 0.090 |
Why?
| | Lung | 1 | 2023 | 3752 | 0.090 |
Why?
| | Infant | 1 | 2024 | 8992 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 1973 | 0.070 |
Why?
| | Male | 4 | 2021 | 63194 | 0.060 |
Why?
| | Child | 1 | 2023 | 20805 | 0.050 |
Why?
| | Iraq | 1 | 2019 | 53 | 0.040 |
Why?
| | Afghanistan | 1 | 2019 | 71 | 0.040 |
Why?
| | Measles Vaccine | 1 | 2019 | 20 | 0.040 |
Why?
| | Hawaii | 1 | 2018 | 41 | 0.040 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2019 | 89 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2019 | 627 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2019 | 2541 | 0.030 |
Why?
| | False Negative Reactions | 1 | 2014 | 51 | 0.030 |
Why?
| | Gene Silencing | 1 | 2014 | 185 | 0.030 |
Why?
| | Cough | 1 | 2012 | 116 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2012 | 164 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2012 | 148 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1417 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5376 | 0.020 |
Why?
| | Chronic Disease | 1 | 2012 | 1706 | 0.020 |
Why?
| | Young Adult | 1 | 2019 | 12389 | 0.010 |
Why?
| | Child, Preschool | 1 | 2014 | 10450 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 31074 | 0.010 |
Why?
| | Adolescent | 1 | 2012 | 20301 | 0.010 |
Why?
|
|
Gross's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|